Loading patent…
AssigneeAbbott Laboratories
InventorsPATRICIA A. BILLING-MEDEL, MAURICE COHEN, TRACEY L. COLPITTS, JULIAN GORDON, EDWARD N. GRANADOS, JOHN C. RUSSELL, STEPHEN D. STROUPE
Estimating the term…
A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as PCIGF and transcribed from prostate tissue, is described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, in vivo imaging, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the prostate, such as prostate cancer. Also provided are antibodies which specifically bind to PCIGF-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific PCIGF polypeptide, which molecules are useful for the therapeutic treatment of prostate diseases, tumors or metastases.
A method of detecting the presence of a target PCIGF polynucleotide in a test sample, said method comprising:
A method for detecting PCIGF mRNA in a test sample, said method comprising:
A method of detecting a target PCIGF polynucleotide in a test sample suspected of containing said target polynucleotide comprising:
A test kit useful for detecting PCIGF polynucleotide in a test sample, said test kit comprising a container containing at least one PCIGF polynucleotide having at least 50% identity with a sequence derived from the region spanning nucleotides 629-1201, inclusive, of SEQUENCE ID NO 1, or fragments or complements thereof.
A purified polynucleotide derived from a PCIGF nucleic acid molecule, wherein said polynucleotide has at least 50% identity with a sequence derived from the region spanning nucleotides 629-1201, inclusive, of SEQUENCE ID NO 1, or fragments or complements thereof.
A recombinant expression system comprising a nucleic acid sequence derived from a PCIGF polynucleotide, wherein said nucleic acid sequence is operably linked to a control sequence compatible with a desired host, and said nucleic acid sequence has at least 50% identity with a sequence derived from the region spanning nucleotides 629-1201, inclusive, of SEQUENCE ID NO 1, or fragments or complements thereof.
A PCIGF polypeptide having less than the full-length amino acid sequence of PCIGF shown in SEQUENCE ID NO 6, wherein said polypeptide comprises an amino acid sequence having at least 50% identity with an amino acid sequence selected from the group consisting of amino acids 220-308 of SEQUENCE ID NO 6 or a fragment thereof, SEQUENCE ID NOS 7-9, and fragments of SEQUENCE ID NOS 7-9.
A specific binding molecule which binds to at least one PCIGF epitope derived from a polypeptide having less than the full-length amino acid sequence of PCIGF shown in SEQUENCE ID NO 6 and which comprises an amino acid sequence having at least 50% identity with an amino acid sequence selected from the group consisting of amino acids 220-308 of SEQUENCE ID NO 6 or a fragment thereof, SEQUENCE ID NOS 7-9, and fragments of SEQUENCE ID NOS 7-9.
A test kit for determining the presence of PCIGF antigen or anti-PCIGF antibody in a test sample, said kit comprising a container containing a PCIGF polypeptide having less than the full-length amino acid sequence of PCIGF shown in SEQUENCE ID NO 6 and which comprises an amino acid sequence having at least 50% identity with an amino acid sequence selected from the group consisting of amino acids 220-308 of SEQUENCE ID NO 6 or a fragment thereof, SEQUENCE ID NOS 7-9, and fragments of SEQUENCE ID NOS 7-9.
A method for producing a polypeptide comprising at least one PCIGF epitope, said method comprising incubating host cells that have been transfected with an expression vector containing a polynucleotide sequence encoding a polypeptide, wherein said polypeptide has less than the full-length amino acid sequence of PCIGF shown in SEQUENCE ID NO 6 and comprises an amino acid sequence having at least 50% identity with an amino acid sequence selected from the group consisting of amino acids 220-308 of SEQUENCE ID NO 6 or a fragment thereof, SEQUENCE ID NOS 7-9, and fragments of SEQUENCE ID NOS 7-9.
A method for detecting the presence of antibodies specific for a PCIGF antigen in a test sample suspected of containing such antibodies, said method comprising:
A method for producing antibodies which specifically bind to PCIGF antigen, comprising administering to an individual an isolated immunogenic polypeptide in an amount sufficient to elicit an immune response, wherein said immunogenic polypeptide comprises at least one PCIGF epitope and is derived from a polypeptide having less than the full-length amino acid sequence of PCIGF shown in SEQUENCE ID NO 6 and which comprises an amino acid sequence having at least 50% identity with an amino acid sequence selected from the group consisting of amino acids 220-308 of SEQUENCE ID NO 6 or a fragment thereof, SEQUENCE ID NOS 7-9, and fragments of SEQUENCE ID NOS 7-9.
A method for producing antibodies which specifically bind to PCIGF antigen, comprising administering to an individual a plasmid comprising a sequence which encodes at least one PCIGF epitope derived from a polypeptide having less than the full-length amino acid sequence of PCIGF shown in SEQUENCE ID NO 6 and which comprises an amino acid sequence having at least 50% identity with an amino acid sequence selected from the group consisting of amino acids 220-308 of SEQUENCE ID NO 6 or a fragment thereof, SEQUENCE ID NOS 7-9, and fragments of SEQUENCE ID NOS 7-9.
A method of distinguishing between prostate cancer and benign prostatic hyperplasia in an individual comprising:
A method of distinguishing between prostate cancer and benign prostatic hyperplasia in an individual comprising:
A method of distinguishing between prostate cancer and benign prostatic hyperplasia in an individual comprising:
A method of distinguishing between prostate cancer and benign prostatic hyperplasia in an individual comprising:
Dependencies are inferred from the claim text.